cyclophosphamide + doxorubicin + fluorouracil + methotrexate + vincristine

This is a combination chemotherapy regimen consisting of five cytotoxic agents: cyclophosphamide, doxorubicin, fluorouracil (5-FU), methotrexate, and vincristine. Each drug has a distinct mechanism of action targeting different aspects of cancer cell biology: - Cyclophosphamide is an alkylating agent that cross-links DNA strands, inhibiting DNA replication and leading to cell death. - Doxorubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, causing double-strand breaks in DNA. - Fluorouracil (5-FU) is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - Methotrexate is a folate analog that inhibits dihydrofolate reductase, blocking the synthesis of nucleotides required for DNA replication. - Vincristine binds to tubulin and prevents microtubule formation during mitosis. This combination targets rapidly dividing cancer cells through multiple mechanisms. While combinations such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or FAC/CMF regimens (combinations including cyclophosphamide, doxorubicin or methotrexate with 5-FU) are well-established in clinical practice for lymphomas and breast cancer[3][6][9], the specific five-drug combination listed here does not correspond to a widely recognized standard regimen but represents an intensive multi-agent chemotherapy approach.